Constellation Pharmaceuticals (NASDAQ:CNST) Stock Price Up 12.8%

Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) traded up 12.8% during mid-day trading on Thursday . The company traded as high as $23.31 and last traded at $22.86. 1,256,590 shares changed hands during trading, an increase of 141% from the average session volume of 520,753 shares. The stock had previously closed at $20.26.

A number of equities research analysts have commented on the company. BMO Capital Markets reduced their price objective on Constellation Pharmaceuticals from $34.00 to $28.00 and set a “market perform” rating for the company in a research note on Thursday, August 6th. Brookline Capital Management started coverage on shares of Constellation Pharmaceuticals in a research note on Thursday, September 3rd. They set a “buy” rating and a $33.00 price target for the company. BidaskClub lowered shares of Constellation Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 24th. Oppenheimer reissued a “hold” rating and set a $20.00 target price on shares of Constellation Pharmaceuticals in a research report on Thursday, September 24th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Constellation Pharmaceuticals in a research report on Sunday, August 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $43.20.

The company has a current ratio of 19.17, a quick ratio of 19.17 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $1.09 billion, a P/E ratio of -7.64 and a beta of 2.90. The stock’s 50-day simple moving average is $21.81 and its 200-day simple moving average is $30.15.

Constellation Pharmaceuticals (NASDAQ:CNST) last announced its earnings results on Wednesday, August 5th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.06). On average, equities research analysts expect that Constellation Pharmaceuticals Inc will post -2.75 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Constellation Pharmaceuticals by 17.9% in the 1st quarter. Rhumbline Advisers now owns 23,974 shares of the company’s stock valued at $754,000 after purchasing an additional 3,643 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Constellation Pharmaceuticals by 19.7% in the 1st quarter. Bank of New York Mellon Corp now owns 61,165 shares of the company’s stock worth $1,922,000 after buying an additional 10,049 shares during the last quarter. State Street Corp grew its position in Constellation Pharmaceuticals by 28.2% during the first quarter. State Street Corp now owns 351,644 shares of the company’s stock valued at $11,052,000 after buying an additional 77,400 shares during the period. Victory Capital Management Inc. increased its holdings in Constellation Pharmaceuticals by 28,992.3% during the first quarter. Victory Capital Management Inc. now owns 654,285 shares of the company’s stock worth $20,564,000 after buying an additional 652,036 shares during the last quarter. Finally, Citigroup Inc. raised its position in Constellation Pharmaceuticals by 110.4% in the first quarter. Citigroup Inc. now owns 6,519 shares of the company’s stock worth $205,000 after acquiring an additional 3,420 shares during the period.

About Constellation Pharmaceuticals (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Story: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.